First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
★ Analysts see FY2026 revenue reaching $146M — +36.9% growth in a single year.
Why Revenue Could Explode
1MIPLYFFA commercial uptake metrics - new patient starts, persistence rates, and quarterly prescription volumes in NPC population
2KP1077 regulatory milestones - FDA Complete Response Letter resolution, potential approval timing for idiopathic hypersomnia indication with estimated 37,000 US patients
3Clinical trial readouts for pipeline assets including potential label expansions or new indications
4Cash runway updates and financing events - equity raises, debt facilities, or partnership announcements given negative $100M+ annual cash burn
5Payer coverage decisions and reimbursement approvals for MIPLYFFA affecting revenue trajectory
growth - Attracts speculative biotech investors focused on binary regulatory catalysts and rare disease commercial potential.
Rising rates negatively impact valuation multiples for pre-profitable biotech as discount rates increase on future cash flows.
Watch on earnings: MIPLYFFA quarterly patient enrollment and net revenue per patient trends, KP1077 FDA regulatory action dates and approval probability updates, Quarterly operating cash burn rate and cash/equivalents balance.
One Sentence Summary:
The bull case is simple: analysts see revenue climbing from $146M to $182M as miplyffa commercial uptake metrics - new patient starts, persistence rates.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.